S-1 plus cisplatin-based chemoradiotherapy after induction chemotherapy for locally advanced gastric adenocarcinoma : phase II trial

Yonsei University Health System, Severance Hospital0 个研究点目标入组 42 人开始时间: 待定最近更新: 2019年4月23日

试验速览

暂无简介。

•1. Histologically confirmed gastric cancer
•2. Performance status of Eastern Cooperative Oncology Group 0 to 1.
•3.Patients without prior therapy (radiotherapy, chemotherapy)
•4.At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria.
•5. Adequate normal organ and marrow function
•6. A patient who understands that he or she has read and understood the written consent of the patient or their legal guardian and that they have signed the consent form and have the right to withdraw their consent at any time without penalty

•1. Patients with distant metastases.
•2. Diagnostic laparoscopic peritoneal metastases confirmed to be inoperable
•3. Unregulated viral infections
•: HIV(human immunodeficiency virus), B-viral hepatitis or C-viral hepatitis
•4. Women with pregnancy (will) or pregnant and lactating women
•5. Hypersensitivity or history of medication used
•6. Patients with significant cardiovascular disease, complications or infection not medically controlled
•- cerebrovascular disease within 1 year
•- Heart disease: myocardial infarction within 1 year, unregulated hypertension, unstable angina, New York Heart Association class 2-4 heart failure, serious arrhythmia requiring treatment
•- Severe injuries, moderate surgery, open biopsy within 28 days.
•- Severe irreversible wounds, ulcers, fractures
•- Wasting hemorrhagic disease without bleeding
•- Recent active gastrointestinal tract infectious
•7. Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ.
•8. Those taking medicines that can cause drug interactions with TS-1

发起方